Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 04 04:00PM ET
1.70
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-1.24 Insider Own43.40% Shs Outstand48.26M Perf Week-0.58%
Market Cap82.04M Forward P/E- EPS next Y-0.94 Insider Trans0.00% Shs Float27.31M Perf Month-1.16%
Income-59.60M PEG- EPS next Q-0.27 Inst Own25.98% Short Float0.30% Perf Quarter2.41%
Sales0.66M P/S124.30 EPS this Y28.07% Inst Trans-4.45% Short Ratio1.57 Perf Half Y-6.59%
Book/sh2.78 P/B0.61 EPS next Y20.04% ROA-32.72% Short Interest0.08M Perf Year11.11%
Cash/sh2.86 P/C0.59 EPS next 5Y- ROE-37.08% 52W Range1.22 - 2.32 Perf YTD-13.71%
Dividend Est.- P/FCF- EPS past 5Y-7.46% ROI-42.97% 52W High-26.72% Beta0.49
Dividend TTM- Quick Ratio15.32 Sales past 5Y280.42% Gross Margin-7.13% 52W Low39.34% ATR (14)0.05
Dividend Ex-Date- Current Ratio15.32 EPS Y/Y TTM23.33% Oper. Margin-9755.24% RSI (14)47.82 Volatility2.68% 2.93%
Employees43 Debt/Eq0.06 Sales Y/Y TTM-95.28% Profit Margin-9043.85% Recom1.50 Target Price3.00
Option/ShortNo / Yes LT Debt/Eq0.03 EPS Q/Q46.88% Payout- Rel Volume0.51 Prev Close1.70
Sales Surprise- EPS Surprise17.61% Sales Q/Q-100.00% EarningsNov 07 BMO Avg Volume52.42K Price1.70
SMA20-0.77% SMA50-0.56% SMA2006.69% Trades Volume28,492 Change0.00%
Date Action Analyst Rating Change Price Target Change
May-29-24Downgrade Wedbush Outperform → Neutral $8 → $2
Sep-22-23Initiated Wedbush Outperform $11
May-04-23Resumed H.C. Wainwright Buy $18
Dec-23-21Initiated H.C. Wainwright Buy $25
May-05-21Resumed Credit Suisse Outperform $30
Apr-26-21Resumed Credit Suisse Outperform $30
Apr-20-21Initiated William Blair Outperform
Apr-20-21Initiated Jefferies Buy
Apr-20-21Initiated Credit Suisse Outperform $30
Nov-07-24 08:30AM
Aug-08-24 04:15PM
May-29-24 07:39AM
May-28-24 04:42PM
04:15PM
08:52PM Loading…
May-13-24 08:52PM
04:45PM
Apr-10-24 08:00AM
Mar-12-24 08:00AM
Feb-27-24 08:00AM
Feb-21-24 04:15PM
Feb-14-24 09:35AM
Jan-24-24 09:35AM
Jan-19-24 06:25AM
Jan-18-24 04:05PM
07:00AM Loading…
Nov-09-23 07:00AM
Nov-07-23 08:00AM
Sep-27-23 09:01AM
Sep-05-23 08:00AM
Aug-12-23 08:07AM
Aug-10-23 09:30AM
08:00AM
06:08AM
Aug-08-23 08:24AM
Aug-07-23 07:00AM
Jun-20-23 08:50AM
Jun-05-23 02:59PM
Jun-02-23 08:50AM
May-24-23 08:00AM
May-16-23 08:29AM
09:05AM Loading…
May-15-23 09:05AM
07:50AM
07:45AM
06:01AM
May-10-23 05:35PM
08:42AM
May-08-23 12:07PM
May-04-23 09:00PM
May-03-23 08:50AM
May-02-23 09:29PM
Apr-20-23 08:00AM
Apr-17-23 09:00AM
06:48AM
Mar-14-23 08:15AM
07:00AM
Mar-07-23 08:00AM
Mar-06-23 08:00AM
Mar-01-23 07:13AM
Feb-28-23 08:00AM
Dec-22-22 07:13AM
Dec-19-22 04:30PM
Nov-28-22 12:11PM
08:00AM
Nov-22-22 07:30AM
Nov-11-22 10:05AM
Nov-10-22 09:00AM
Nov-07-22 09:25AM
08:48AM
08:05AM
Oct-26-22 07:30AM
Oct-18-22 07:30AM
Oct-05-22 08:05AM
Sep-22-22 06:25AM
Sep-06-22 07:30AM
Aug-12-22 07:41AM
Aug-11-22 08:45AM
07:30AM
Jul-14-22 10:43AM
Jul-06-22 07:00AM
Jun-22-22 07:00AM
Jun-14-22 09:13AM
May-18-22 07:00AM
May-15-22 08:41AM
May-13-22 08:28AM
May-12-22 08:35AM
07:00AM
May-11-22 08:44AM
07:32AM
May-02-22 07:00AM
Apr-28-22 07:00AM
Apr-13-22 07:00AM
Apr-12-22 02:01PM
Mar-28-22 05:37PM
Mar-17-22 07:00AM
Mar-07-22 04:30PM
Mar-01-22 07:00AM
Feb-03-22 04:35PM
Jan-26-22 07:00AM
Dec-24-21 12:38AM
Dec-23-21 06:05AM
Dec-18-21 12:38AM
Dec-17-21 08:00AM
Dec-08-21 07:00AM
Nov-12-21 07:00AM
Nov-10-21 07:00AM
Nov-04-21 07:00AM
Nov-02-21 08:00AM
Oct-07-21 09:00AM
Oct-01-21 08:15AM
Sep-02-21 07:00AM
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.